Metabolic diabetes reversal
Instead of glucose monitoring, insulin injection and new drugs to rival insulin, some companies are taking a different route to treating diabetes, including Fractyl Health and Twin Health.
In April, Fractyl garnered FDA breakthrough device designation for its Revita DMR procedure designed to resurface the upper intestine lining (duodenal mucosa) in metabolic disease for patients with insulin-treated type 2 diabetes. Through the procedure, the company aims to minimize or eliminate the need for type 2 diabetes patients to receive insulin treatment. CEO Harith Rajagopalan said in an interview earlier this year that the aim is to “reverse insulin resistance.”
Twin Health develops the Whole Body Digital Twin platform designed to help reverse and prevent chronic metabolic diseases while improving energy and health. The platform uses thousands of data points collected daily through non-invasive, wearable sensors and self-reported preferences to provides individualized nutrition, sleep, activity and breathing guidance to patients and healthcare providers in an effort to reverse and prevent multiple chronic metabolic diseases, including type 2 diabetes. The company raised $140 million in a Series C financing round in October.
